Kiran Mazumdar-Shaw, Biocon executive chair (Photo by Indranil Aditya/NurPhoto via AP)
December 2, 2024 01:11 PM EST
Pharma
FDA+

Bio­con lands FDA ap­proval for an­oth­er Ste­lara biosim­i­lar

Katherine Lewin

News Reporter

Bio­con Bi­o­log­ics scored an FDA ap­proval for its Ste­lara biosim­i­lar, mar­ket­ed as Yesin­tek, the com­pa­ny an­nounced Mon­day.

Bio­con en­tered in­to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Ole­ma, No­var­tis ink an­oth­er agree­ment, this time for a late-stage breast can­cer tri­al

A service from the Financial Times